Cancer Network
Home to the journal Oncology, Cancer Network provides research and opinion on the screening, early detection, diagnosis, treatment, and prevention of cancers.
Related Articles
Perseverance Underscores Success in Rare Lymphoma Research
The efficacy of the BOVen regimen in chronic lymphocytic leukemia facilitated its evaluation in patients with mantle cell lymphoma.
Atezolizumab/Trastuzumab Plus Chemotherapy Shows Efficacy in Gastric Cancer
Pathological complete response was higher among patients with ERBB2–positive gastric cancer or GEJ adenocarcinoma treated with atezolizumab vs without.
Ileal Free Flap Urethroplasty May Remedy Devastated Bladder Outlet
A new type of robotic posterior surgery has been shown to be a treatment option for patients with devastated bladder outlets.
T-DXd Plus THP Bolsters Pathologic Responses in Early-Stage Breast Cancer
Neoadjuvant trastuzumab deruxtecan/THP showed an enhanced safety profile vs the standard-of-care regimen in patients with early-stage breast cancer.
FDA Grants Accelerated Approval to Avutometinib/Defactinib in KRAS+ LGSOC
Findings from the phase 2 RAMP 201 trial support the FDA approval of avutometinib plus defactinib in low-grade serous ovarian cancer.
CancerNetwork® Face-Off
Face-Off by CancerNetwork® is not your typical oncology discussion—it’s a high-energy, head-to-head showdown where top cancer institutions debate the latest breakthroughs in a debate. With…
FDA Lifts Clinical Hold on Tabelecleucel in EBV+ Lymphoproliferative Disease
Investigators can restart the phase 3 ALLELE trial assessing tabelecleucel for patients with EBV-related post-transplant lymphoproliferative disease.
Acalabrutinib Combo Receives EU Approval for Mantle Cell Lymphoma
Support for the decision follows a positive opinion from the Committee for Medicinal Products for Human Use based on the phase 3 ECHO trial results.
Leveraging Beta and Alpha Emitters in Metastatic CRPC Management
Beta emitters like 177Lu-rosopatamab may offer built-in PSMA imaging during the treatment of patients with metastatic castration-resistant prostate cancer.
Divarasib Combo Appears “Promising” in Pretreated KRAS G12C+ NSCLC
Ongoing ctDNA analysis may elucidate outcomes associated with divarasib plus migoprotafib for those with KRAS G12C–positive NSCLC.